Jakob Albrethsen, Peter Busch Østergren, Pernille Badsberg Norup, Jens Sønksen, Mikkel Fode, Caroline Kistorp, Nikolai B Nordsborg, Sara Amalie Solheim, Jakob Mørkeberg, Katharina M Main, Anders Juul
BACKGROUND: Serum INSL3 is a Leydig cell biomarker, but little is known about the circulating concentration of INSL3 during hypothalamus-pituitary-testicular suppression. AIM: To study the concomitant changes in serum concentrations of INSL3, testosterone and LH during experimental and therapeutic testicular suppression. METHODS: We included serum samples from three different cohorts comprising subjects before and after testicular suppression; 1) Six healthy young men who were treated with androgens (Sustanon®, Aspen Pharma, Dublin, Ireland), 2) Ten transgender girls (male sex assigned at birth) who were treated with three-monthly GnRH agonist injections (Leuprorelinacetat, Abacus Medicine, Copenhagen, Denmark) and 3) Fifty-five patients with prostate cancer who were randomized to surgical castration (bilateral subcapsular orchiectomy) or treatment with GnRH agonist (Triptorelin, Ipsen Pharma, Kista, Sweden)...
May 26, 2023: Journal of Clinical Endocrinology and Metabolism